Geographic Atrophy (GA) Market: 2023 Analysis, Size, Key Players, Industry Research Trends & Forecast 2030

1
Geographic Atrophy (GA) Market Size, Share and
Industry Growth Analysis Report 2023-2030
2
Summary
Geographic Atrophy (GA) Market Report 2023-2030
SNS INSIDER
This forecast anticipates the Geographic Atrophy
(GA) Market to expand at a compound annual growth
rate (CAGR) of 7.2 during the forecast period
from 2023 to 2030. This projection indicates
sustained growth in the market for treatments
and therapies addressing GA, a progressive and
irreversible condition affecting the macula,
leading to vision loss. The expected growth
underscores the increasing prevalence of
age-related macular degeneration (AMD), of which
GA is a significant subtype, particularly in
aging populations worldwide. Factors
contributing to this growth trajectory may
include advancements in diagnostic techniques,
evolving treatment modalities such as gene
therapies and pharmacological interventions, and
a greater understanding of the disease
pathophysiology. Additionally, initiatives aimed
at raising awareness about AMD and GA, coupled
with efforts to improve access to healthcare
services, could further drive market expansion.
This forecast provides valuable insights for
pharmaceutical companies, healthcare providers,
regulatory authorities, and other stakeholders
involved in the management and treatment of
Geographic Atrophy.
3
Market Growth Driver
Geographic Atrophy (GA) Market Report 2023-2030
SNS INSIDER
The Geographic Atrophy (GA) market is
experiencing notable growth driven by several key
factors. One of the primary drivers is the
increasing prevalence of age-related macular
degeneration (AMD), of which GA is an advanced
form. As the global population ages, the
incidence of AMD is rising, leading to a growing
patient population in need of treatment. GA,
characterized by progressive degeneration of the
macula and loss of central vision, represents a
significant unmet medical need, driving research
and development efforts to discover effective
therapies. Moreover, advancements in imaging
technologies, such as optical coherence
tomography (OCT) and fundus autofluorescence
(FAF), have improved the diagnosis and monitoring
of GA, further fueling market growth.
Additionally, the evolving regulatory landscape
and increasing investments in ophthalmic
research are driving innovation in GA
therapeutics, with several promising candidates
in clinical development.
4
Market Opportunities
Geographic Atrophy (GA) Market Report 2023-2030
SNS INSIDER
Alongside growth drivers, the GA market presents
various opportunities and challenges.
Opportunities lie in the development of novel
treatment approaches targeting the underlying
pathophysiology of GA, such as complement
inhibition, neuroprotection, and regenerative
medicine. Advances in drug delivery technologies,
including sustained-release implants and gene
therapies, offer opportunities for targeted and
sustained drug delivery to the retina, enhancing
therapeutic efficacy and patient compliance.
Moreover, partnerships between pharmaceutical
companies, academic institutions, and advocacy
groups offer opportunities for collaboration and
co-development of innovative therapies that
address the multifactorial nature of GA. However,
challenges such as the complex etiology of GA,
variability in disease progression, and the need
for robust clinical trial endpoints pose
significant hurdles. Ensuring the safety,
efficacy, and accessibility of GA therapies, as
well as addressing regulatory requirements and
reimbursement considerations, are critical
challenges that need to be overcome to realize
the full potential of the GA market. Regional
Overview In terms of regional overview, the GA
market exhibits diverse dynamics across different
regions. North America leads the market, driven
by a large patient population, advanced
healthcare infrastructure, and a robust pipeline
of GA therapeutics in clinical development.
Europe represents another significant market,
characterized by increasing awareness of AMD and
growing investments in ophthalmic research. The
Asia Pacific region is witnessing rapid growth,
fueled by rising healthcare expenditure,
increasing prevalence of AMD, and a growing
focus on ophthalmic innovation in countries like
China, India, and Japan. Emerging markets in
Latin America and the Middle East Africa also
present opportunities for market expansion,
although challenges such as limited access to
healthcare and affordability constraints may
hinder adoption.
5
Geographic Atrophy (GA) Market Report 2023-2030
SNS INSIDER Overall, the GA market is poised for
continued growth globally, driven by ongoing
advancements in research and development and
efforts to address the unmet medical needs of
patients with AMD and GA. Top Key
Players BioPoint Inc., PPD Inc., Icon Plc, RHO,
Inc. KPS Life, LLC, IQVIA Inc., Parexel
International Corporation, Wuxi AppTec Co., Ltd.
Quanticate International Limited, Laboratory
Corporation of America Holdings
Market Segmentation
By Type (Clinical Monitoring, Medical Writing,
Data Management, Pharmacovigilance,
Biostatistics/Programming, Regulatory Affairs) By
Stage (Clinical Development, Post Approval) By
Application (Biopharma Companies, Biotech
Companies, Medical Devices Companies, Research
Centers And Academic Institutes)
6
ABOUT US
Geographic Atrophy (GA) Market Report 2023-2030
SNS INSIDER

SNS Insider is a market
research company that delivers evidence-based
strategies for clients seeking growth.
Headquartered in India, we've developed to serve
our clients as they seek new growth possibilities
throughout the world. We have the worldwide
reach of a large research firm, but the agility
and individualized attention of a small
boutique. We're flexible and collaborative, with
real ties between our operations. What's the
result? Wherever
7

• Geographic Atrophy (GA) Market Report 2023-2030
  SNS INSIDER
• you are in the world, you'll have access to our
  global network of sector and methodology experts,
  as well as the deep cultural awareness required
  to ensure your project's success.
• We offer our clients an integrated data and
  research solution drawing on the companys three
  core
• competencies
• Syndicate
• Custom
• Consulting
• We manage the full research process from primary
  data collecting to final report with our in-house
  staff of Field Interviewers. Our researchers and
  analysts work together to analyse all study data
  and findings. On our custom-built data platform,
  SNS has established a proprietary market size
  model for every business sector. Our consultants
  also help clients evaluate and apply research
  findings and recommendations in their own
  companies.